For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Filgotinib - Inflammatory bowel disease
PAD Profile : Filgotinib - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Budesonide
- Tofacitinib
- Methotrexate
- Mesalazine (Systemic)
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found on the IBD guidelines page.
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the use of filgotinib for treating moderately to severely active ulcerative colitis in line with NICE TA792.
Filgotinib will be given a RED traffic light status. Prescribing will be by hospital specialists only using Blueteq forms for initiation & continuation
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.